ClinicalTrials.gg

Program

arexvy

Also written as “RSVPreF3 OA investigational vaccine”, “RSVPreF3 OA vaccine” and “RSVPreF3 OA Investigational Vaccine”.

Its studies are mostly in Respiratory Syncytial Virus Infections, led by GlaxoSmithKline.

Furthest: phase 3, since Jan 27, 202118 company-led studies, 3 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline183 open or runningphase 3since Jan 27, 2021Jan 11, 2019none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 1 study since Jan 11, 2019.

  1. Sep 12, 2019Phase 1 study in Respiratory Syncytial Virus InfectionsNCT04090658 · 40 enrolled · Japan
  2. Dec 1, 2020Phase 2 study in Respiratory Syncytial Virus InfectionsNCT04657198 · 126 enrolled · United States, Belgium
  3. Jan 27, 2021Phase 3 study in Respiratory Syncytial Virus InfectionsNCT04732871 · 1,720 enrolled · United States, Finland, Germany and more
  4. Apr 8, 20212 phase 3 studies in Respiratory Syncytial Virus InfectionsNCT04841577, NCT04886596
  5. Sep 17, 2021Phase 3 study in Respiratory Syncytial Virus InfectionsNCT05059301 · 770 enrolled · United States, Canada, Sweden
  6. Sep 26, 2022Phase 3 study in Respiratory Syncytial Virus InfectionsNCT05559476 · 1,029 enrolled · United States
  7. Oct 3, 20222 phase 3 studies in Respiratory Syncytial Virus InfectionsNCT05568797, NCT05590403
  8. Jun 16, 2023Phase 2 study in Respiratory Syncytial Virus InfectionsNCT05921903 · 386 enrolled · United States, Australia, Canada and more
  9. Jul 21, 2023Phase 3 study in Respiratory Syncytial Virus InfectionsNCT05966090 · 530 enrolled · United States, Canada
  10. Apr 16, 20242 phase 3 studies in Respiratory Syncytial Virus InfectionsNCT06374394, NCT06389487
  11. Jul 30, 2024Phase 3 study in Respiratory Syncytial Virus InfectionsNCT06534892 · 10,212 enrolled · United States, Australia, Belgium and more
  12. Aug 9, 2024Phase 3 study in Respiratory Syncytial Virus InfectionsNCT06551181 · 2,620 enrolled · China, Finland, Japan and more
  13. Sep 24, 2024Phase 3 study in Respiratory Syncytial Virus InfectionsNCT06614725 · 751 enrolled · India
  14. Oct 21, 2025Phase 3 study in Respiratory Syncytial Virus InfectionsNCT07220109 · 750 enrolled · China

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“A respiratory syncytial virus (RSV) vaccine, that can potentially be used for the active immunization and prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 60 years of age and older”NCIt, by rule
“Fusion glycoprotein F0 vaccine antigen”ChEMBL 37, by rule

Studies

All 18 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07220109Respiratory Syncytial Virus Infections · China3Active, not recruitingJul 20, 2026750
NCT06614725Respiratory Syncytial Virus Infections · India3CompletedJun 3, 2025751
NCT06551181Respiratory Syncytial Virus Infections · China, Finland, Japan and more3CompletedApr 24, 20252,620
NCT06534892Respiratory Syncytial Virus Infections · United States, Australia, Belgium and more3Active, not recruitingSep 30, 202610,212
NCT06389487Respiratory Syncytial Virus Infections · United States, Australia, Canada and more3CompletedJul 29, 20241,459
NCT06374394Respiratory Syncytial Virus Infections · United States, Belgium, Netherlands and more3CompletedNov 1, 2024841
NCT05966090Respiratory Syncytial Virus Infections · United States, Canada3CompletedFeb 19, 2024530
NCT05921903Respiratory Syncytial Virus Infections · United States, Australia, Canada and more2CompletedJun 25, 2024386
NCT05590403Respiratory Syncytial Virus Infections3CompletedMar 13, 20231,544
NCT05568797Respiratory Syncytial Virus Infections · Belgium, Finland, France and more3CompletedFeb 17, 20231,045
NCT05559476Respiratory Syncytial Virus Infections · United States3CompletedMar 7, 20231,029
NCT05059301Respiratory Syncytial Virus Infections · United States, Canada, Sweden3CompletedJan 24, 2022770
NCT04886596Respiratory Syncytial Virus Infections · United States, Australia, Belgium and more3CompletedApr 11, 202226,675
NCT04841577Respiratory Syncytial Virus Infections · New Zealand, Panama, South Africa3CompletedSep 22, 2021976
NCT04732871Respiratory Syncytial Virus Infections · United States, Finland, Germany and more3Active, not recruitingJun 6, 20221,720
NCT04657198Respiratory Syncytial Virus Infections · United States, Belgium2CompletedJun 3, 2021126
NCT04090658Respiratory Syncytial Virus Infections · Japan1CompletedJan 10, 202040
NCT03814590Respiratory Syncytial Virus Infections · United States, Belgium2CompletedDec 12, 20191,053

How it is read

Names in the registry

  • “RSVPreF3 OA investigational vaccine”, 10 entries
  • “RSVPreF3 OA vaccine”, 4 entries
  • “RSVPreF3 OA Investigational Vaccine”, 1 entry
  • “RSV Vaccine (GSK3844766A) unadjuvanted low dose”, 1 entry
  • “RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01E”, 1 entry

Codes read as this program: GSK3844766A.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.